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Abstract
Purpose: Today, cancers have become a major cause of mortality in developed and developing countries. Among various
cancers, gastric cancer imposes a huge economic burden on patients, their families, and on the health-care system. This study
aimed to determine the economic burden of gastric cancer in Kohgiluyeh and Boyer Ahmad province of Iran in 2016.
Methods: This was a cross-sectional cost of illness study conducted in Kohgiluyeh and Boyer Ahmad province of Iran in 2016,
using a prevalence-based approach. All patients were studied using the census method (N ¼ 110). The required data on direct
medical, direct nonmedical, and indirect costs were collected using a data collection form from the patients’ medical records,
tariffs of diagnostic, and therapeutic services approved by the Ministry of Health and Medical Education in 2016.
Results: The total cost and burden of gastric cancer in Kohgiluyeh and Boyer Ahmad province of Iran in 2016 were $US436 237,
among which the majority were direct medical costs (59%). The highest costs among direct medical costs, direct nonmedical
costs, and indirect costs were, respectively, related to the costs of medications used by the patients (35%), transportation (31%),
and absence of patients’ families from work and daily activities caused by patient care (56%).
Conclusion: Our study has revealed for the first time high costs of gastric cancer in Iran. To decrease the total costs and burden,
the following suggestions can be made: increasing insurance coverage and government subsidies for purchasing necessary
medications, providing the required specialized care and services related to cancer diseases such as gastric cancer in other
provincial cities rather than just in capital cities, and so on.
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Introduction
Cancer is the second cause of death globally,1 and the number
of people with cancer is increasing.2 Historically, gastric can-
cer has been one of the major causes of deaths due to cancer in
the world.3 Gastric cancer is the fifth most common cancer in
the world, and more than a million new cases are detected every
year. The incidence of gastric cancer is particularly high in East
Asia, followed by Central and Eastern Europe, and South
America.4 Gastric cancer is one of the main causes of death
due to cancer in the 21st century. It is anticipated that by 2030,
gastric cancer will be one of the main causes of mortality in the
world, and by 2050, there will be 2.5 million new cases and 1.9
million deaths. The prognosis of this disease is poor, and its
5-year survival rate in most countries ranges from 10% to 40%
and is around 20% in most developing countries, while in Japan
it is 40% to 60%. In Iran, the 5-year survival is relatively low at
28%.5,6 Gastric cancer has remained a major public health issue
worldwide, despite a steady reduction in its incidence and mor-
tality rate in the past 30 years. Annually, more than 870 000
new cases of this disease are reported in the world, and more
than 650 000 people in the world die due to this cancer. The
estimated incidence rate in Iran is about 7300 cases per year
and is the first cause of cancer deaths in both genders.7 In Iran,
according to the Iran Cancer Research Center, gastric cancer is
the most common cancer in men and the third most common
cancer in women after breast and colon cancers.8 Furthermore,
based on the official statistics of the Ministry of Health and
Medical Education, over the past few years, especially since
the beginning of the 2010s, cancer and, more commonly, gas-
tric cancer in the province of Kohgiluyeh and Boyer Ahmad
have been widespread. According to the data registered in the
Iran Cancer Registration System affiliated to the Health Deputy
of Yasuj University of Medical Sciences in 2016, the total
number of patients with cancer in this province was 446, of
which 155 people, that is, about one-third of all cancers, had
been diagnosed with gastric cancer. The number of patients
with gastric cancer registered in this province over the past few
years has shown an increasing trend.3 Gastric cancer is a multi-
factorial disorder, with aging, male sex, lifestyle, environmen-
tal and genetic factors, and Helicobacter pylori infection
among its known risk factors.9 Gastric cancer is characterized
by nonspecific symptoms such as dyspepsia, weight loss, and
anemia, making its early detection and diagnosis difficult.
Therefore, when the disease is diagnosed it is usually advanced,
and treatments become more complex and costly.10 The results
of a study showed that the burden of gastric cancer and the
number of disability-adjusted life-years in the province of Koh-
giluyeh and Boyer Ahmad in 2015 was 754.03 years, indicating
a high burden of disease.11 On the other hand, cancer, espe-
cially gastric cancer, in addition to their high burden of disease
which leads to a reduction in production and productivity in the
economy, imposes heavy costs on households and the health
system. These costs are also very important from the societal
perspective and account for 5% to 10% of the total health-care
costs in most developed countries.12 Among various cancers,
gastric cancer imposes a huge economic burden on the affected
person and the health-care system. Gastric cancer is considered
as a serious illness in terms of control and treatment, and its
medical costs are almost 10 times higher than other noncancer-
ous diseases. Also, the medical costs of patients with advanced
gastric cancer are higher than those of patients with gastric
cancer whose stage of the disease is unclear.13
Only a few studies have been conducted on the economic
burden of gastric cancer, such as studies conducted by Haga
et al14 in Japan and Kim et al15 in South Korea, which have
reported its economic burden at $US11 billion and $US2.8
billion, respectively. Moreover, Mariotto et al16 in their study
have estimated the direct costs of gastric cancer in the United
States at $US1.82 billion. Also, Khorasani et al in their study
have reported the total cost of productivity loss caused by pre-
mature deaths due to gastric cancer in Iran in 2012 as US$209
920 163,17 and Karami-Matin et al in their study have reported
that in Iran during 2006 to 2010, the costs increased from
US$45 850 250 in 2006 to $US51 273 537 in 2010.6
Despite the high prevalence of gastric cancer in Iran, there
are no comprehensive studies investigating the economic bur-
den of this disease. Therefore, faced with increasing numbers
of gastric cancer in Kohgiluyeh and Boyer Ahmad province in
Iran, we conducted a study to determine the economic burden
of gastric cancer in this province in 2016.
Materials and Methods
This was a cross-sectional cost of illness study conducted to
determine the economic burden of gastric cancer in Kohgiluyeh
and Boyer Ahmad province in Iran in 2016. Kohgiluyeh and
Boyer Ahmad is 1 of the 31 provinces of Iran located in the
southwest of the country and its capital is Yasuj. In general,
there are 2 approaches for calculating the economic burden of
diseases, including incidence-based and prevalence-based
approaches.18 In the present study, the prevalence-based
approach was used, and the economic burden of gastric cancer
was estimated from the patients’ perspective. In the
prevalence-based approach, the costs of a disease associated
with a time period (often 1 year) due to the prevalence during
the same period, irrespective of the onset time of the disease,
are estimated.18 Therefore, in this study, the costs of all patients
with gastric cancer, including patients whose illness started in
2016 or before, was calculated for 2016. The study population
consisted of all patients with a definitive diagnosis of gastric
cancer in Kohgiluyeh and Boyer Ahmad province registered in
the Iran Cancer Registration System affiliated to the Health
Deputy of Yasuj University of Medical Sciences in 2016. Of
155 patients registered in this system, 45 patients were
excluded from the study due to missing key data, and the rest
were studied using census method. Inclusion criteria were
patients diagnosed with gastric cancer based on the 10th revi-
sion of the International Statistical Classification of Diseases
and Related Health Problems (C16) in 2016 in Kohgiluyeh and
Boyer Ahmad province and the patients and their families’
willingness to participate in the study. Exclusion criteria
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included patients and their families’ unwillingness to partici-
pate in the study, incomplete patients’ medical records, and
having other diseases and cancers as comorbidities. The present
study was approved by the ethics committee of Shiraz Univer-
sity of Medical Sciences (Project No. 95-01-07-11299).
Informed consent was obtained from all patients participating
in the study.
In this study, the required data were collected using a data
collection form consisting of 2 parts. The first part was related
to patients’ demographic characteristics, and the second part
was included items related to the costs. Costs were divided into
2 main categories: direct and indirect costs. Direct costs were
divided into medical and nonmedical costs. Direct medical
costs included costs related to physicians and oncologists’ vis-
its, emergency department visits, chemotherapy, surgical ser-
vices, laboratory tests, ultrasonography, magnetic resonance
imaging, computed tomography scan, radiology, radiotherapy,
endoscopy, colonoscopy, transfer by ambulance, patient hospi-
talization, and medications used by patients. These costs were
calculated using the patients’ medical records available in the
Health Deputy of Yasuj University of Medical Sciences and
hospitals to which patients were admitted in 2016 as well as
tariffs of diagnostic and therapeutic services approved by the
Ministry of Health and Medical Education in 2016 available in
the Treatment Deputy of Yasuj University of Medical Sciences.
Direct nonmedical costs included the costs of transportation,
accommodation, meals for the patient and relatives, patient
consumables, and the costs of accommodation for people who
visit the patient at his or her home, which were calculated by
asking patients and their families. Indirect costs were calcu-
lated from productivity losses of patients and their families due
to absence from work and daily activities caused by illness or
patient care, calculated using the human capital approach.19
For collecting and calculating the required data on indirect
costs, 2 methods were used simultaneously because of the need
to obtain 1-year-old data from the studied patients and in order
to minimize the possible recall bias. First, indirect costs were
calculated using data obtained directly from the patients and
their families. Second, indirect costs were calculated by the
researchers based on the patients and their relatives’ employ-
ment status, the patients’ physical condition, the minimum
wage determined by the Ministry of Labor and Social Welfare,
and the amount of income lost by the patients’ relatives.
Finally, the mean of these 2 numbers, obtained directly from
the patients and their families and from other sources by
researchers, was considered as indirect costs. In order to make
international comparisons, all costs were converted into the US
dollar using the exchange rate of each US dollar equaling to 30
221 Rials in 2016.20 The collected data were analyzed using
Excel 2013.
Results
The results showed that most of the studied patients were male
(77%), in the age-group of 55 to 65 years (39%), married
(99%), illiterate or with elementary education level (77%), had
rural health insurance coverage (48%) and no supplementary
insurance coverage (81%), had monthly income between
US$193.53 and 303.89 (43%), and had malignant tumors
(60%; Table 1).
Furthermore, the results showed that the total costs of gastric
cancer in Kohgiluyeh and Boyer Ahmad province in 2016 were
US$436 237, in which the direct medical costs were 59%,
indirect costs were 28%, and direct nonmedical costs were
13% of total costs. Mean costs per patient were US$3966. The
total and mean direct medical costs in 2016 were US$258 466
and US$2350, respectively, in which the major costs were
related to the costs of medications used (35.32% of total direct
medical costs), chemotherapy (14% of total direct medical
costs), and laboratory tests (11% of total direct medical costs),
respectively. Moreover, the total and mean direct nonmedical
costs in 2016 were US$57 431 and US$522, respectively, in
which the major costs were related to the costs of transportation
(31% of total direct nonmedical costs), accommodation (22%
of total direct nonmedical costs), and accommodation for peo-
ple who visit the patient at his or her home (17% of total direct
nonmedical costs). Also, the total and mean indirect costs in
2016 were US$120 340 and US$2, in which the major costs













Illiterate or with elementary education level 85 (77)
Guidance school and diploma 19 (17)
Associate and bachelor’s degree 4 (4)
Higher than bachelor’s degree 2 (2)
Types of basic health insurance
Iran health insurance 20 (18)
Social security insurance 31 (28)
Armed forces medical services insurance 2 (1.8)
Rural health insurance 53 (48)
Imdad (Relief) committee health insurance 4 (4)
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were related to the absence of patients’ families from work and
daily activities caused by patient care (56% of total indirect
costs; Table 2).
Discussion
This study was conducted to determine the economic burden of
gastric cancer in Kohgiluyeh and Boyer Ahmad province of
Iran in 2016. The results showed that most of the studied
patients with gastric cancer diagnosis were male, in the age-
group of 55 to 65 years, married, illiterate or with elementary
education level, had rural health insurance coverage and no
supplementary insurance coverage, and had monthly income
between US$199 and US$331, consistent with studies from
other countries.21-24 Based on the results of the present study,
the total costs and economic burden of gastric cancer in Koh-
giluyeh and Boyer Ahmad province of Iran in 2016 were esti-
mated to be US$436 237, in which the highest were related to
the direct medical costs indicating that the decreases in the
direct medical costs for patients with gastric cancer could sig-
nificantly reduce the economic burden of gastric cancer in
Kohgiluyeh and Boyer Ahmad. Kim et al 15 in their study found
that the economic burden of gastric cancer in South Korea was
estimated to be US$2.8 billion, in which the lowest costs were
related to the direct nonmedical costs. Hong et al4 in their study
estimated the economic burden of advanced gastric cancer in
Taiwan at US$423 million, the lowest of which were related to
direct nonmedical costs. The results of these 2 studies are in
line with those of the current study. In the studies conducted by
Kim et al and Hong et al, the highest costs were related to
indirect costs, which are not consistent with the results of the
present study. It should be noted that the great difference in the
economic burden of gastric cancer between the present study
and the Hong et al’s and Kim et al’s studies can be due to the
estimation of gastric cancer only in 1 of the provinces of Iran in
the present study, while in 2 other studies the burden of gastric
cancer had been calculated in the whole country of Taiwan and
South Korea. On the other hand, in the study of Hong et al, the
burden of advanced gastric cancer had been estimated which
had led to higher costs and economic burden because the stud-
ied patients were in the advanced stages of gastric cancer, and
they needed more diagnostic and therapeutic measures.
Undoubtedly, early diagnosis of the disease and effective treat-
ment can significantly reduce the economic burden imposed on
the patients with gastric cancer as well as the society. Also, the
results of the present study showed that the total and mean
direct medical costs in Kohgiluyeh and Boyer Ahmad province
in 2016 were US$258 466 and US$2350, respectively, in which
the highest and lowest direct medical cost was related, respec-
tively, to the medications used by patients and transfer by
ambulance. The reasons for the high costs of medications used
by the studied patients were that such medications are very
expensive and some of them are not covered by the health
insurance organizations. On the other hand, the reason for the
low costs of transferring by ambulance is that there is usually
no urgent and immediate transfer of patients with gastric cancer
to medical centers, and basically their required services, such
as chemotherapy, laboratory tests, ultrasonography, and so on,
are provided as elective services and according to a specific and
determined schedule and timetable. In the study of Izadi et al,
the medication costs accounted for the largest share of direct
medical costs for patients with gastric cancer in Kerman,25
which are consistent with those of the present study. Further-
more, the results represented that the total and mean direct
nonmedical costs in Kohgiluyeh and Boyer Ahmad province
in 2016 were estimated to be US$57 431 and US$522, respec-
tively, in which the highest and lowest direct nonmedical costs
were related to the costs of transportation and patient consum-
ables, respectively. The shortage of public transportation vehi-
cles needed for patients’ transportation in the town as well as
for going to the capital city to receive the required services and
medical treatments and more use of passenger cars and vehicles
with higher costs can be a reason for high costs of transporta-
tion. Considering that consumables are often used for elderly
patients and patients who have entered the final stages of the
Table 2. The Total and Mean Costs of the Studied Patients in Kohgi-












Physicians and oncologists’ visits 22 166 202 9
Emergency department visits 6552 60 3
Chemotherapy 36 541 332 14
Surgical services 24 556 223 10
Laboratory tests 29 593 269 11
Ultrasonography 4608 42 2
MRI 2599 24 1
CT scan 3063 28 1 59
Radiology 3539 32 1
Radiotherapy 5403 49 2
Endoscopy 8419 77 3
Colonoscopy 2808 26 1
Transfer by ambulance 169 2 0.06
Patient hospitalization 17 162 156 7
Medications 91 289 830 35
Total 258 466 2350 100
Direct nonmedical costs
Transportation 17 762 161 31
Accommodation 12 601 115 22
Meals for the patient and relatives 9182 83 16 13
Patient consumables 8154 74 14
Accommodation for people who
visit the patient at his/her home
9732 88 17
Total 57 431 522 100
Indirect costs
Patients’ absence from work and
daily activities caused by illness
52 639 479 44
Absence of patients’ families from
work and daily activities caused
by patient care
67 701 615 56 28
Total 120 340 1094 100
Total costs 436 237 3966 100 100
4 Cancer Control
disease, and given that a small number of patients in the present
study had this feature, the cost of patient consumables was the
lowest cost among the direct nonmedical costs. In the study of
Bazyar et al,26 patients coming from distant areas to the spe-
cialized hospitals and medical centers in big cities for receiving
medical services were faced with higher costs, which is in line
with the results of the current study. The results showed that the
total and mean indirect costs in the studied province in 2016
were US$120 340 and US$1094, respectively, in which the
highest costs were related to the absence of patients’ families
from work and daily activities caused by patient care. This is
because most of the studied patients were elderly and in the
age-group of 55 to 65 and needed to be accompanied by at least
1 of their family members at the time of going to the medical
centers for receiving required services and treatment, and if
they had other disabilities, including motor disabilities, the
number of family members for accompanying them would
increase. This had caused more and longer absence of patients’
families from work and daily activities, and therefore, its costs
were the highest ones. This study had a series of limitations,
including conducting a cross-sectional study as well as the
defects in some of the patients’ medical records.
Conclusion
Based on the results of the present study, the total costs and
economic burden of gastric cancer in Kohgiluyeh and Boyer
Ahmad province of Iran in 2016 was US$436 237, in which the
highest costs were, respectively, related to the direct medical
costs (the costs of medications used by patients), indirect costs
(absence of patients’ families from work and daily activities
caused by patient care), and direct nonmedical costs (the costs
of transportation). Given the high out-of-pocket costs of med-
ications used patients with gastric cancer, health insurance
coverage and government subsidies for purchasing the neces-
sary medications by these patients should be increased. Also, it
is recommended that the required specialized care and services
related to gastric cancer should be provided in provincial cities
as well as capital cities so that patients do not have to go to the
capital cities to receive such services, and this will greatly
decrease the direct nonmedical costs, including the costs of
accommodation and transportation. Moreover, if there is a pos-
sibility of performing laboratory tests for Helicobacter pylori
(the most important cause of gastric cancer) in all patients with
gastrointestinal diseases such as gastric ulcer, gastritis, and so
on by the Ministry of Health and Medical Education subsidies
or medical insurance organizations, if it is cost-effective, and
treating patients with positive test result, the incidence of gas-
tric cancer will significantly decrease in Kohgiluyeh and Boyer
Ahmad province. Providing training courses on the prevention
of gastric cancer at an early age and before the onset of the
disease and sharing required information on the disease during
these training courses or in the mass media can help to raise
public awareness about the ways of preventing gastric cancer.
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